Page 2 - Christopher Posner News Today

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease -associated pruritus in adult... | June 11, 2023

A small molecule drug has been recommended by England’s National Institute for Health Care and Excellence (NICE) for the treatment of adults with moderate to severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis.

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) CEO Christopher Posner sold 3,869 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $4.40, for a total value of $17,023.60. Following the transaction, the chief executive officer now directly owns 172,514 shares in the company, […]

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 4,840,000 shares, a decline of 9.4% from the March 31st total of 5,340,000 shares. Based on an average daily volume of 642,000 shares, the […]

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $9.31 and traded as low as $3.90. Cara Therapeutics shares last traded at $3.93, with a volume of 511,942 shares changing hands. Analyst […]

Intrepid Financial Planning Group LLC decreased its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) by 20.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,500 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. Intrepid […]

Pinnacle Associates Ltd. decreased its stake in Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 687,885 shares of the biopharmaceutical company’s stock after selling 17,482 shares during the quarter. Pinnacle Associates Ltd. owned approximately 1.28% […]

STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new...

Assenagon Asset Management S.A. raised its position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) by 210.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 101,544 shares of the biopharmaceutical company’s stock after purchasing an additional 68,844 shares during the […]

Several brokerages have updated their recommendations and price targets on shares of Cara Therapeutics (NASDAQ: CARA) in the last few weeks: 3/16/2023 – Cara Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 3/7/2023 – Cara Therapeutics was downgraded by analysts at Bank of America Co. from a […]